Tuesday, June 11, 2019Markets yesterday closed in the green, with the Nasdaq accumulating gains as the day went one while the Dow basically halved its market open level. But we’re up again in this morning’s pre-market, on basically the same data we had a day ago: the Mexican tariff threat is off the table, while economic reads are apparently softening after weeks and months of clear strength.
Even with the prospect of Mexican tariffs hitting the market, such as what we saw last week, positive sentiment ruled: a 5% tax on Mexican imports would likely have stifled goods production domestically, which would likely have forced the Fed’s hand in cutting interest rates from their current 2.5%. This looked very attractive to traders, even as the rate remained beneath the Fed’s long-term neutral setting of around 3%. But cheap money is cheap money!
There have been other signs that the robust economy is coming under pressure in recent weeks and months, including lower reads in Durable Goods, Capital Spending (following Q1 GDP north of 3% largely on business investment), Retail Earnings, Freight Shipments and Jobs Numbers. Are these enough on their own — without the threat of new tariffs bumping up the price of goods — to convince the Fed to set a new downward trend in interest rates? So far, analysts don’t think so.
A new read on the Producer Price Index (PPI) for May showed further signs of slight weakness, though overall results were in-line with expectations: +0.1% on headline PPI was as predicted, as was the +0.2% print subtracting food and energy costs. Monthly trade doubled expectations to +0.4%, while Final Demand was lower at +1.8%, and down from the previous read’s +2.2%.
Analysts — and Fed voting parties — tend to wait for the other shoe to drop, meanning Consumer Price Index (CPI) figures, which are due tomorrow morning. But from the producer side, we still see slightly incremental inflation, like we’ve seen month over month for the past few years, more or less. Thus, no clear reason to raise interest rates to counter rampant inflation.
Then again, we still don’t see much impetus for the Fed to take down interest rates based on any of these new economic data points. So why are market futures still looking so strong? Because when headlines aren’t too hot and aren’t too cold, we have a term for that: Goldilocks.
Mark Vickery
Senior Editor
Questions or comments about this article and/or its author? Click here>>
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Tuesday, June 11, 2019
Markets yesterday closed in the green, with the Nasdaq accumulating gains as the day went one while the Dow basically halved its market open level. But we’re up again in this morning’s pre-market, on basically the same data we had a day ago: the Mexican tariff threat is off the table, while economic reads are apparently softening after weeks and months of clear strength.
Even with the prospect of Mexican tariffs hitting the market, such as what we saw last week, positive sentiment ruled: a 5% tax on Mexican imports would likely have stifled goods production domestically, which would likely have forced the Fed’s hand in cutting interest rates from their current 2.5%. This looked very attractive to traders, even as the rate remained beneath the Fed’s long-term neutral setting of around 3%. But cheap money is cheap money!
There have been other signs that the robust economy is coming under pressure in recent weeks and months, including lower reads in Durable Goods, Capital Spending (following Q1 GDP north of 3% largely on business investment), Retail Earnings, Freight Shipments and Jobs Numbers. Are these enough on their own — without the threat of new tariffs bumping up the price of goods — to convince the Fed to set a new downward trend in interest rates? So far, analysts don’t think so.
A new read on the Producer Price Index (PPI) for May showed further signs of slight weakness, though overall results were in-line with expectations: +0.1% on headline PPI was as predicted, as was the +0.2% print subtracting food and energy costs. Monthly trade doubled expectations to +0.4%, while Final Demand was lower at +1.8%, and down from the previous read’s +2.2%.
Analysts — and Fed voting parties — tend to wait for the other shoe to drop, meanning Consumer Price Index (CPI) figures, which are due tomorrow morning. But from the producer side, we still see slightly incremental inflation, like we’ve seen month over month for the past few years, more or less. Thus, no clear reason to raise interest rates to counter rampant inflation.
Then again, we still don’t see much impetus for the Fed to take down interest rates based on any of these new economic data points. So why are market futures still looking so strong? Because when headlines aren’t too hot and aren’t too cold, we have a term for that: Goldilocks.
Mark Vickery
Senior Editor
Questions or comments about this article and/or its author? Click here>>
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on QQQ - FREE
Get the latest research report on SPY - FREE
Get the latest research report on DIA - FREE